Overview

UARK 2014-08 A Phase II Open-Label, Multiple-Dose, Single Agent Study to Evaluate the Overall Response Rate of Orally Administered Trametinib

Status:
Withdrawn

Trial end date:
2016-04-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the overall response rate of Trametinib when administered orally to patients with relapsed or refractory multiple myeloma

Phase:

Phase 2

Details

Lead Sponsor:

University of Arkansas

Treatments:

Trametinib